opicapone (Rx)

Brand and Other Names:Ongentys
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 25mg
  • 50mg

Parkinson Disease

Indicated as an adjunct to levodopa/carbidopa to reduce OFF episodes in patients with Parkinson disease

50 mg PO qHS

Dosage Modifications

Renal impairment

  • Mild-to-moderate (CrCl 30-89 mL/min): No dosage adjustment necessary
  • Severe (CrCl<30 mL/min): Not studied; owing to the potential for increased exposure, monitor for adverse reactions and discontinue therapy if tolerability issues arise
  • End-stage renal disease (ESRD) (CrCl <15 mL/min): Avoid use

Hepatic impairment

  • Mild (Child-Pugh A): No dosage adjustment necessary
  • Moderate (Child-Pugh B): 25 mg PO qHS
  • Severe (Child-Pugh C): Avoid use

Dosing Considerations

When discontinuing therapy, monitor patients and consider adjustment of other dopaminergic therapies as needed

European Drug Information

Click here to view drug information in Europe

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and opicapone

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (3)

            • isocarboxazid

              opicapone, isocarboxazid. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and opicapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.

            • phenelzine

              opicapone, phenelzine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and opicapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.

            • tranylcypromine

              opicapone, tranylcypromine. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Both nonselective MAO inhibitors and opicapone inhibit catecholamine metabolism, leading to increased levels of catecholamines. Potential for dangerously high HR or BP.

            Serious - Use Alternative (0)

              Monitor Closely (8)

              • dobutamine

                opicapone will increase the level or effect of dobutamine by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • dopamine

                opicapone will increase the level or effect of dopamine by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • epinephrine

                opicapone will increase the level or effect of epinephrine by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • epinephrine inhaled

                opicapone will increase the level or effect of epinephrine inhaled by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • epinephrine racemic

                opicapone will increase the level or effect of epinephrine racemic by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • isoproterenol

                opicapone will increase the level or effect of isoproterenol by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • methyldopa

                opicapone will increase the level or effect of methyldopa by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              • norepinephrine

                opicapone will increase the level or effect of norepinephrine by decreasing metabolism. Use Caution/Monitor. Opicapone is a COMT inhibitor. Caution if coadministered with drugs metabolized by COMT. If coadministered, monitor for changes in heart rate, heart rhythm, and blood pressure.

              Minor (0)

                Previous
                Next:

                Adverse Effects

                >10%

                Dyskinesia (20%)

                1-10%

                Constipation (6%)

                Increased blood creatine kinase (5%)

                Hypotension/syncope (5%)

                Hypotension/syncope (5%)

                Decreased weight (4%)

                Hypertension (3%)

                Dry mouth (3%)

                Dizziness (3%)

                Hallucination (3%)

                Previous
                Next:

                Warnings

                Contraindications

                Concomitant use of nonselective monoamine oxidase (MAO) inhibitors

                History of pheochromocytoma, paraganglioma, or other catecholamine-secreting neoplasm

                Cautions

                Patients treated with dopaminergic medications and/or medications that increase levodopa exposure have reported falling asleep while engaged in activities of daily living (eg, operating motor vehicles); advise not to drive and to avoid other potentially dangerous activities

                Hypotension (orthostatic and nonorthostatic), syncope, and presyncope occurred; monitor for hypotension; if hypotension occurs, consider discontinuing or adjusting dosage of other medications that may lower blood pressure

                May potentiate the effects of levodopa and may cause or exacerbate dyskinesia; consider levodopa or dopaminergic medication dose reduction

                Hallucinations, delusions, agitation, or aggressive behavior occurred; consider discontinuing if hallucinations or psychoticlike behaviors occur; avoid treating patients with a major psychotic disorder because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone

                May intensify urges (eg, gambling, increased sexual activity, spending, binge eating) and the inability to control these urges while taking one or more dopaminergic therapies that increase central dopaminergic tone; reevaluate and consider discontinuing therapy if urges develop during treatment

                Symptoms resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, have been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central dopaminergic tone; when discontinuing therapy, monitor and consider adjustment of other dopaminergic therapies as needed

                Drug interaction overview

                • Opicapone is a substrate of P-gp, BCRP, MRP2, OATP1B2, and OATP2B1 transporters; no clinically significant transporter-mediated interaction is expected for opicapone
                • Nonselective MAO inhibitors
                  • Coadministration is contraindicated
                  • Concomitant use with nonselective MAO inhibitors (eg, phenelzine, isocarboxazid, tranylcypromine) may inhibit catecholamine metabolism, leading to increased levels of catecholamines
                  • Selective MAO-B inhibitors can be used concomitantly with opicapone
                • Drugs metabolized by catechol-O-methyltransferase (COMT)
                  • Use with caution
                  • Coadministration with drugs metabolized by COMT may affect the pharmacokinetics of those drugs, which may increase the risk of possible arrhythmias, increased heart rate, and excessive changes in blood pressure
                  • Monitor for changes in heart rate, rhythm, and blood pressure in patients concomitantly treated with opicapone and drugs metabolized by COMT

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy

                No adequate data available on use in pregnant females

                Animal data

                • Oral administration during pregnancy resulted in adverse effects on embryofetal development (increased incidence of fetal abnormalities) at clinically relevant plasma exposure in one of two species tested
                • In addition, opicapone is always coadministered with levodopa/carbidopa, which is known to cause development toxicity in rabbits

                Lactation

                No data available on drug presence in human milk and its effects on breastfeeding or milk production

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Once daily, peripheral-acting, COMT inhibitor; decreases conversion rate of levodopa to 3-O-methyldopa, thereby prolonging levodopa half-life to reduce motor fluctuations

                Absorption

                Peak plasma time: 2 hr

                Effects of food

                • After a moderate-fat/moderate-calorie meal, mean peak plasma concentration decreased 62%, mean AUC decreased 31%, delayed peak plasma time by 4 hr

                Distribution

                Protein bound: >99% (independent of concentration)

                Metabolism

                Primary metabolic pathway: Sulphation

                Other metabolic pathways: Glucuronidation, methylation (by COMT), reduction, and glutathione conjugation

                Elimination

                Mean half-life: 1-2 hr

                Excretion

                • Feces: 70% (22% unchanged)
                • Expired: 20%
                • Urine: 5% (<1 unchanged)
                Previous
                Next:

                Administration

                Oral Administration

                Administer at bedtime

                Do not eat food for 1 hr before and for at least 1 hr after administration

                Missed dose: Take dose at the next scheduled time

                Storage

                Capsules: Store at <30ºC (86ºF)

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                Additional Offers
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.